Literature DB >> 16463595

Living arrangements of individuals with schizophrenia in Japan: impact of community-based mental health services.

Iwao Oshima1, Eri Kuno.   

Abstract

AIMS: In Japan psychiatric hospitals and family play the predominant roles in caring for people with serious mental illness. This study explored how the introduction of community-based care has changed this situation by examining living arrangements of individuals with schizophrenia who were treated in one of the most progressive systems in Japan (Kawasaki) compared with national norms.
METHODS: The proportion of clients with schizophrenia in the community versus hospital and living arrangements for those in the community were compared between the Kawasaki and national treated population, using data from the Kawasaki psychiatric service users survey in 1993 and two national surveys in 1993 and 1983. The variation in living arrangements was examined across five different age cohorts.
RESULTS: The estimated national population was 36.7, which was similar to 32.7 clients per 10,000 population in Kawasaki. Some 71% of the Kawasaki clients were treated in the community compared with 55% nationally. The difference between the Kawasaki and national populations was the largest among clients aged 40 to 59. The Kawasaki community clients had a higher proportion of clients living alone.
CONCLUSIONS: The community mental health services available in Kawasaki appeared to reduce hospitalisation and help clients to live alone in the community.

Entities:  

Mesh:

Year:  2006        PMID: 16463595     DOI: 10.1177/0020764006061249

Source DB:  PubMed          Journal:  Int J Soc Psychiatry        ISSN: 0020-7640


  2 in total

1.  Extraordinary Care for Extraordinary Conditions: Constructing Parental Care for Serious Mental Illness in Japan.

Authors:  Ellen B Rubinstein
Journal:  Cult Med Psychiatry       Date:  2018-12

2.  Productivity and deadweight losses due to relapses of schizophrenia in Japan.

Authors:  Yusuke Nakamura; Jörg Mahlich
Journal:  Neuropsychiatr Dis Treat       Date:  2017-05-17       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.